
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a publicly listed company based in Menlo Park (United States) founded in 2019 by David Socks. Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. Phathom Pharmaceuticals has raised $90 million across 2 funding rounds from investors including SVB, Janus Henderson Investors and RA Capital. The company has 427 employees. Its chief executive, as recorded, is David Socks. Phathom Pharmaceuticals offers products and services including VOQUEZNA. Its focus areas include Life Sciences, Rare Diseases, Drugs and GI. Its legal entity is PHATHOM PHARMACEUTICALS, INC. Its competitors include Lumena Pharma and Ellodi Pharmaceuticals; 1 of its 2 listed competitors has raised funding.
Company details
Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.
- Headquarters Menlo Park, United States
- Employees 427
- Founders David Socks
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website phathompharma.com
- Social LinkedIn X
- Legal Name Phathom Pharmaceuticals, Inc.
- Annual Revenue$175.11 M (USD)216.93as on Dec 31, 2025
- Net Profit-$221.25 M (USD)33.82as on Dec 31, 2025
- EBITDA-$159.35 M (USD)42.4as on Dec 31, 2025
- Total Equity Funding$90M (USD)
in 2 rounds
- Latest Funding Round$90M (USD), Series C
May 2019
- InvestorsSVB
& 9 more
- Employee Count427
Products & Services of Phathom Pharmaceuticals
Phathom Pharmaceuticals offers a comprehensive portfolio of products and services, including VOQUEZNA.
Treats acid-related damage and heartburn for GI disorders in adults.
Funding Insights of Phathom Pharmaceuticals
Phathom Pharmaceuticals has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90M
- Total Rounds 2
- Last Round Series C — $90M
- First Round $50M
(May 2019)
- Investors Count 10
All 2 funding rounds of Phathom Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $90M | Series C | – | Frazier Healthcare Partners | |
| May 2019 | $50M | Debt – Conventional | – | – |
10 investors in total: 10 institutional.
Investors in Phathom Pharmaceuticals
Phathom Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Diversified investment management firm | 2000 | greenspringassociates.com | Owings Mills, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Investments in multiple sectors are made by Sahsen Ventures. | sahsen.com | Seattle, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Provides grants for conservation, economic development, and social impact programs. | 1947 | rkmf.org | Pittsburgh, United States |
Investor details for Phathom Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Phathom Pharmaceuticals
22 people are tracked at Phathom Pharmaceuticals (11 in leadership, 6 in board & advisors, 5 in team); the tracked headcount is 427.
| Name | Role | Group |
|---|---|---|
David Socks | Co-Founder & CEO | Leadership |
Terrie Curran | CEO & President | Leadership |
Eckhard Leifke | Chief Medical Officer | Leadership |
Christine Fischer | Vice President, Commercial Insights & Analytics | Leadership |
Melissa Tankiewicz | Director, Human Resources HRBP | Leadership |
Dahua R. | Director Of Sales Marketing | Leadership |
Barbara Gluck | Director Sales Operations | Leadership |
Shawn Peter | Area Sales Director | Leadership |
Julie Israel | Area Sales Director | Leadership |
Joann Napolitano | Director Talent Acquisition | Leadership |
Azmi Nabulsi | COO | Leadership |
Michael Cola | Director | Board & advisors |
Frank Karbe | Director | Board & advisors |
Heidi Kunz | Director | Board & advisors |
Mark Stenhouse | Director | Board & advisors |
Asit Parikh | Director | Board & advisors |
Tadataka Yamada | Chairman | Board & advisors |
Erin Maher | Sales Operations Manager | Team |
Dax Davila | Territory Sales Representative | Team |
Samantha Stuewer | Territory Sales Representative | Team |
2 more people are available in the full profile.
Complete people profiles for Phathom Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Phathom Pharmaceuticals
Phathom Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol PHAT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Oct 2019
- Listed onNASDAQ: PHAT
- Listed entityPhathom Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS71722W1071
- Share price$7.00 (-1.82% on the day) · 2026-10-13
- Market capitalisation$566.3M
- EPS (diluted, trailing year)$-1.27
- Volume (last session)1,947,160
Financials of Phathom Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $175.1M | -$221.2M | -$159.3M |
| 2024 | $55.2M | -$334.3M | -$276.7M |
| 2023 | $682,000 | -$201.6M | -$166.7M |
| 2022 | -$197.7M | -$171.8M | |
| 2021 | -$143.9M | -$134.6M |
Detailed financial statements for Phathom Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Phathom Pharmaceuticals
3 dated milestones of Phathom Pharmaceuticals, from founding to its latest funding, stage changes and deals.
- Founded Phathom Pharmaceuticals is founded.
- Funding First funding round of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Phathom Pharmaceuticals
Phathom Pharmaceuticals has 2 listed competitors in our database, 1 of them funded. They include Lumena Pharma and Ellodi Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lumenapharma.com | 2011 | San Diego, United States | $71.05M | 11 | Passionately pursuing better treatments for adults and children with rare liver diseases. | |
| ellodipharma.com | 2020 | Ewing Township, United States | Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals. |
Detailed competitors of Phathom Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Phathom Pharmaceuticals
The website of Phathom Pharmaceuticals (phathompharma.com) receives about 9.3K visits a month and ranks #3,173,971 among all websites worldwide, #4,177 in Biotechnology and Pharmaceuticals.
- Monthly visits9.3K
▲ 49.1% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,173,971
among all websites
- Category rank#4,177
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.8
- Average visit33 sec
- DevicesDesktop 39% · Mobile 61%
Top companies in Rare Diseases
3 companies that operate in the same segment as Phathom Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phathom Pharmaceuticals
Complete news archive for Phathom Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phathom Pharmaceuticals
Phathom Pharmaceuticals was founded in 2019.
Phathom Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
David Socks is the CEO of Phathom Pharmaceuticals, as recorded in our data. They have also founded this company.
Phathom Pharmaceuticals is a funded company, having raised a total of $90M across 2 funding rounds to date. The company's 1st funding round was a Series C of $90M, raised on May 2019.
Phathom Pharmaceuticals has 427 employees.
Annual revenue of Phathom Pharmaceuticals is $175.11M as on Dec 31, 2025.
Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.
Phathom Pharmaceuticals's top competitors include Lumena Pharma and Ellodi Pharmaceuticals.
Phathom Pharmaceuticals offers VOQUEZNA.
Yes, Phathom Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol PHAT.
Phathom Pharmaceuticals has 10 investors. Key investors include SVB, Janus Henderson Investors, RA Capital, Frazier Healthcare Partners, and Abingworth.
Phathom Pharmaceuticals operates through Phathom Pharmaceuticals, Inc..
